GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market cap, addressing...
NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...
Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is gone -...
COVID-19 Immunity From mRNA Booster Does Not Last Very Long.
Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to 115 days...
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we follow, shows a spike in either...
GeoVax to Present at World Vaccine Congress, Thursday April 4th.
Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation non-MRNA Covid-19 vaccine candidate on Thursday, April 4, 2024, 12:00...
IMAC Holdings (BACK) Explodes 94% Higher Post Reverse Split, With 42 Million Shares Trading...
Simply Incredible! 2024 Will be the Year of Post Reverse Split Revenge!
Taking advantage of post reverse-split investor pessimism, is a VALID investing technique.
IMAC owns and...
China Remains at Risk to Future MonkeyPox Outbreaks.
GeoVax (GOVX) intends to become the first U.S.-based supplier of the MVA vaccine to prevent Mpox and smallpox.
The World Health Organization just updated global...
GeoVax Live Webcast
Tonight, Monday at 5:30 PM. And You Don't Fly to Newport Beach and Deal With all the Drinking, Investment Bankers, and Hedge Fund Managers,...
Killer, 44-Page Report on GeoVax (GOVX).
And a Nine-Page Summary Report..Great Weekend Reading.
This is one killer report. In fact if we might be so bold, we might even call it...
U.S. Population Classified as ‘Immunocompromised’ Explodes Higher, in Latest JAMA Report.
New report nearly doubles the GeoVax addressable market of Immunocompromised Patients (i.e. potential customers) from 15 Million, to 23 Million patients! Not updated were...
Latest article
Cabaletta (CABA) Surges 44% on Massive Volume Spike.
Biotech 12 Pack Off to Nice Start..
Cabaletta up 35%, GeoVax up 75%, and Replimune up 62%. All since late April!
Biotech Stock Review is...
GeoVax (GOVX) Surges 51% on Massive Volume Spike.
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Wednesday afternoon, the 29th, while we were nearing completion of an updated...
Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
